Home » Newsletters » BioWorld Science

BioWorld Science

July 25, 1997

View Archived Issues

HRT inhibits ACE in postmenopausal women

HRT indicated in hypertensive women

Peptide antibiotic isolated from human psoriatic skin

Tularik and Roche Bioscience collaborate on antiinflammatory drug discovery

Cambridge NeuroScience awarded SBIR grant for cancer research

Synsorb Biotech begins phase III trial for Synsorb Pk

Sparta's oral chemotherapeutic agent enters clinical trials

Microbix receives milestone payment under ThromboClear agreement with Gensia

Joint venture established for transgenic ATIII

R&D at Teikoku Hormone

Novel antiarthritic drug in development at P&U

Selective neuropeptide Y5 receptor antagonists described by Synaptic

NPY antagonists from Thomae

Dura: Q2 1997 highlights

Piperidone and glutarimide neurokinin antagonists developed at Pfizer

DepoTech: Q2 1997 highlights

U.K. university researchers develop new agents for AD

FDA health advisory for Accolate

In vitro activity of new glycopeptide from Lilly

Gatifloxacin: in vitro activity, pharmacokinetics and clinical results

Genetics Institute's growth factor recommended for approval by advisory committee

Antibacterial activity, drug interactions and safety of Bay-12-8039

Yuhan presents new parenteral cephalosporin

Diabetes classification not as clear-cut as previously thought

Pharmacia & Upjohn Japanese pipeline in review

Marketing approval sought for Periostat in Italy

Infant nutrition as a way of preventing IDDM

New approaches to the pharmacological treatment of obesity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...